798 related articles for article (PubMed ID: 32645724)
1. Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice.
Patel V; Joharapurkar A; Kshirsagar S; Patel M; Savsani H; Bahekar R; Jain M
Drug Res (Stuttg); 2020 Aug; 70(8):376-384. PubMed ID: 32645724
[TBL] [Abstract][Full Text] [Related]
2. Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone.
Patel VJ; Joharapurkar AA; Kshirsagar SG; Sutariya BK; Patel MS; Bahekar RH; Jain MR
Curr Mol Pharmacol; 2019; 12(2):139-146. PubMed ID: 30747091
[TBL] [Abstract][Full Text] [Related]
3. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
[TBL] [Abstract][Full Text] [Related]
4. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
[TBL] [Abstract][Full Text] [Related]
5. Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Patel H; Pandey D; Patel D; Bahekar R; Jain M
Biomed Pharmacother; 2018 Feb; 98():364-371. PubMed ID: 29275178
[TBL] [Abstract][Full Text] [Related]
6. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Patel K; Bahekar R; Shah G; Jain M
Can J Physiol Pharmacol; 2013 Dec; 91(12):1009-15. PubMed ID: 24289070
[TBL] [Abstract][Full Text] [Related]
7. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet.
Clemmensen C; Chabenne J; Finan B; Sullivan L; Fischer K; Küchler D; Sehrer L; Ograjsek T; Hofmann SM; Schriever SC; Pfluger PT; Pinkstaff J; Tschöp MH; Dimarchi R; Müller TD
Diabetes; 2014 Apr; 63(4):1422-7. PubMed ID: 24379349
[TBL] [Abstract][Full Text] [Related]
8. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
Lee EY; Kim YW; Oh H; Choi CS; Ahn JH; Lee BW; Kang ES; Cha BS; Lee HC
Metabolism; 2014 Jun; 63(6):793-9. PubMed ID: 24684824
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
10. Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Patel H; Pandey D; Patel D; Ranvir R; Kadam S; Bahekar R; Jain M
Cardiovasc Hematol Agents Med Chem; 2018; 16(1):35-43. PubMed ID: 29357809
[TBL] [Abstract][Full Text] [Related]
11. Peptide-YY
Boland BB; Laker RC; O'Brien S; Sitaula S; Sermadiras I; Nielsen JC; Barkholt P; Roostalu U; Hecksher-Sørensen J; Sejthen SR; Thorbek DD; Suckow A; Burmeister N; Oldham S; Will S; Howard VG; Gill BM; Newton P; Naylor J; Hornigold DC; Austin J; Lantier L; McGuinness OP; Trevaskis JL; Grimsby JS; Rhodes CJ
Mol Metab; 2022 Jan; 55():101392. PubMed ID: 34781035
[TBL] [Abstract][Full Text] [Related]
12. Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model.
Patel V; Joharapurkar A; Kshirsagar S; Patel HM; Pandey D; Patel D; Sutariya B; Patel M; Bahekar R; Jain MR
Drug Res (Stuttg); 2017 Dec; 67(12):730-736. PubMed ID: 28898910
[TBL] [Abstract][Full Text] [Related]
13. Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss.
Liberini CG; Koch-Laskowski K; Shaulson E; McGrath LE; Lipsky RK; Lhamo R; Ghidewon M; Ling T; Stein LM; Hayes MR
Sci Rep; 2019 Jun; 9(1):8447. PubMed ID: 31186439
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.
Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
16. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
[TBL] [Abstract][Full Text] [Related]
17. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.
He M; Su H; Gao W; Johansson SM; Liu Q; Wu X; Liao J; Young AA; Bartfai T; Wang MW
PLoS One; 2010 Dec; 5(12):e14205. PubMed ID: 21151924
[TBL] [Abstract][Full Text] [Related]
18. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease.
Patel V; Joharapurkar A; Kshirsagar S; Patel M; Sutariya B; Patel H; Pandey D; Patel D; Ranvir R; Kadam S; Bahekar R; Jain M
Can J Physiol Pharmacol; 2018 Jun; 96(6):587-596. PubMed ID: 29406832
[TBL] [Abstract][Full Text] [Related]
19. Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Pandey D; Patel H; Ranvir R; Kadam S; Patel D; Bahekar R; Jain M
Chem Biol Interact; 2018 Feb; 282():13-21. PubMed ID: 29325849
[TBL] [Abstract][Full Text] [Related]
20. EGLP-1 lowers body weight better than exendin-4 by reducing food intake and increasing basal energy expenditure in diet-induced obese mice.
Gao H; Zhao Q; Li K; Qin F; Yin X; Lu Z; Song Z; Wu Y; Shen Y; Pan Y; Jin L; Yanfeng Zhang
Exp Cell Res; 2021 Feb; 399(1):112454. PubMed ID: 33359447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
